Clinical trials: Pancreas Carcinoma
Pancreatic Cancer
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
This is an open multicenter randomized phase I/II study. The main purpose with this study is to investigate dose and efficacy of a combination of Irinotecan, Cetuximab and Everolimus given biweekly to patients with local advanced…
- Trial name
- NCT01042028
- Testing
- Everolimus, Cetuximab, Irinotecan, Capecitabine, Oxaliplatine
- Where
- 2 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Per Pfeiffer
Pancreatic Cancer
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Opioid growth factor may stop the growth of pancreatic cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well opioid growth factor works in treating patients with advanced…
- Trial name
- OGF (NCT00109941)
- Testing
- opioid growth factor, metenkephalin, OGF-opioid growth factor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Pancreatic Adenocarcinoma Advanced or Metastatic
Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.
In Brazil pancreatic adenocarcinoma represents 2% of tumors, and 4% mortality being an uncommon disease, however very aggressive.Only 20% of cases are indicated for curative surgery, of which only 20% are alive within 5 years.
- Trial name
- NCT01971034
- Testing
- Paclitaxel, Metformin
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Solid Tumors, Pancreatic Cancer
CTS2190 Phase I /II Clinical Study in Patients
This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types.
- Conditions
- Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer
- Trial name
- NCT06224387
- Testing
- CTS2190 capsules
- Where
- 2 sites in China
- Volunteers
- 224 people
- Sponsor
- CytosinLab Therapeutics Co., Ltd.
Pancreas Neoplasms, Lymphatic Metastasis
Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions
The purpose of this study is to compare the diagnosis accuracy of modified wet suction technique and 5ml dry suction technique on solid occupying lesions.
- Conditions
- Pancreas Neoplasms, Lymphatic Metastasis, Neoplasm Metastases, Unknown Primary Neoplasm Metastasis
- Trial name
- NCT02789371
- Testing
- the first pass is made with 5ml suction technique, the first pass is made with modified wet suction technique
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Bin Cheng
Peritoneal Carcinomatosis, Peritoneal Metastases
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT03682744
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
Pancreatic Cancer, Pancreatic Adenocarcinoma
Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue
Pancreatic cancer is a very aggressive cancer. Over the past 40 years there has not been much progress made in reducing deaths from this cancer.
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Cyst
- Trial name
- NCT03140592
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Stony Brook University
Pancreatic Ductal Adenocarcinoma
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable…
- Trial name
- PANCARDINAL-2 (NCT06831136)
- Testing
- Neoadjuvant Chemotherapy (NAC), Immunotherapy (pembrolizumab), Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pancreatic Cancer
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
The purpose of this study is to assess the efficacy and safety of AZD6244 (ARRY-142886)versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line therapy with gemcitabine.
- Trial name
- NCT00372944
- Testing
- AZD6244, capecitabine
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Bile Duct Cancer
Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
The purpose of this study is to determine whether preoperative immunonutrition is effective on infectious complication and Th1/Th2 differentiation in patients with pancreaticoduodenectomy.
- Trial name
- EPIPD (NCT01256034)
- Testing
- Oral IMPACT
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Chiba University
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
This pilot clinical trial studies a palliative care program in improving the quality of life of patients with newly diagnosed pancreatic cancer.
- Conditions
- Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02307539
- Testing
- Psychosocial Assessment and Care, Palliative Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Cholangiocarcinoma, Pancreatic Cancer
Registry for Advanced Endoscopy
Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Sclerosing Cholangitis
- Trial name
- ERDB (NCT05187312)
- Testing
- Endoscopic retrograde Cholangio- pancreatography, Endoscopic ultrasound
- Where
- Sweden
- Volunteers
- 1,000 people
- Sponsor
- Region Stockholm
Pancreatic Cancer
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in subjects with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT06547736
- Testing
- SHR-A2102 or/and HRS-4642, SHR-A1904 or/and HRS-4642, SHR-A1811 or/and HRS-4642
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with pancreatic, ovarian, and other solid tumors that have…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04616534
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Left-sided Pancreatic Cancer, Ductal Adenocarcinoma
Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
When distal pancreatectomy is carried out for left-sided pancreatic cancer, splenectomy is usually performed not only for margin-negative resection but also for effective clearance of the splenic hilar lymph nodes.
- Trial name
- NCT01875198
- Testing
- Radical Antegrade Modular Pancreatectomy with Splenectomy, Radical Antegrade Modular Pancreatectomy without splenectomy
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Yonsei University
Cancer, Overall Survival
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree…
- Trial name
- METRICS (NCT02201381)
- Testing
- Metabolic treatment
- Where
- United Kingdom
- Sponsor
- Health Clinics Limited
Breast Cancer, Colorectal Cancer
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients with metastatic cancer may help doctors find out how much the cancer has spread.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00898781
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received…
- Conditions
- Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of Prostate
- Trial name
- DeLLight (NCT06893783)
- Testing
- Tarlatamab
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Inkeun Park
Pancreatic Cancer, Advanced Cancer
LY3214996 +/- HCQ in Pancreatic Cancer
This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
- Trial name
- NCT04386057
- Testing
- Hydroxychloroquine Sulfate, LY3214996
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kimberly Perez, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.